advertisement

Topcon

Tanito M 12

Showing records 1 to 12 | Display all abstracts from Tanito M

104438 Nation-Wide Analysis of Glaucoma Medication Prescription in Fiscal Year of 2019 in Japan
Tanito M
Journal of personalized medicine 2022; 12:
104362 Proportion of Glaucoma Types and Surgeries Among Young, Pre-Old, Old, and Oldest-Old Age Groups or Different Sex Groups
Tanito M
Clinical Ophthalmology 2022; 16: 1815-1819
103835 Investigating the clinical usefulness of definitions of progression with 10-2 visual field
Asano S
British Journal of Ophthalmology 2022; 106: 1098-1103
104424 Fingertip-Measured Skin Carotenoids and Advanced Glycation End Product Levels in Glaucoma
Kadoh Y
Antioxidants (Basel, Switzerland) 2022; 11:
103835 Investigating the clinical usefulness of definitions of progression with 10-2 visual field
Murata H
British Journal of Ophthalmology 2022; 106: 1098-1103
104362 Proportion of Glaucoma Types and Surgeries Among Young, Pre-Old, Old, and Oldest-Old Age Groups or Different Sex Groups
Matsuoka Y
Clinical Ophthalmology 2022; 16: 1815-1819
104424 Fingertip-Measured Skin Carotenoids and Advanced Glycation End Product Levels in Glaucoma
Takayanagi Y; Takayanagi Y
Antioxidants (Basel, Switzerland) 2022; 11:
103835 Investigating the clinical usefulness of definitions of progression with 10-2 visual field
Fujino Y
British Journal of Ophthalmology 2022; 106: 1098-1103
104424 Fingertip-Measured Skin Carotenoids and Advanced Glycation End Product Levels in Glaucoma
Sasaki J
Antioxidants (Basel, Switzerland) 2022; 11:
103835 Investigating the clinical usefulness of definitions of progression with 10-2 visual field
Yamashita T
British Journal of Ophthalmology 2022; 106: 1098-1103
104424 Fingertip-Measured Skin Carotenoids and Advanced Glycation End Product Levels in Glaucoma
Tanito M
Antioxidants (Basel, Switzerland) 2022; 11:
103835 Investigating the clinical usefulness of definitions of progression with 10-2 visual field
Miki A; Ikeda Y; Mori K; Tanito M; Asaoka R
British Journal of Ophthalmology 2022; 106: 1098-1103

Issue 23-2

Change Issue


advertisement

Oculus